Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy

Clinical Research in Cardiology

Volumn 104, Issue 11, 2015, Pages 911-917

  Haghikia, Arash ^a   Podewski, Edith ^a   Berliner, Dominik ^a   Sonnenschein, Kristina ^a   Fischer, Dieter ^b   Angermann, Christiane E ^c   Böhm, Michael ^d   Röntgen, Philipp ^a   Bauersachs, Johann ^a   Hilfiker Kleiner, Denise ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Bromocriptine; Heart failure; Peripartum cardiomyopathy; Prolactin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; BROMOCRIPTINE; CREATININE; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN; IVABRADINE; MINERALOCORTICOID ANTAGONIST; NITROGEN; POTASSIUM; SODIUM; UREA;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BEST SUPPORTIVE CARE; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PERIPARTUM CARDIOMYOPATHY; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; CARDIOMYOPATHIES; CLINICAL TRIAL; METHODOLOGY; MULTICENTER STUDY (TOPIC); PERINATAL PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BROMOCRIPTINE; CARDIOMYOPATHIES; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84945468546     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0869-5     Document Type: Article

References (23)

1. Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12:767–778
2. Sliwa K, Fett J, Elkayam U (2006) Peripartum cardiomyopathy. Lancet 368:687–693
3. Kolte D, Khera S, Aronow WS et al (2014) Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 3:e001056
4. Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084
5. Haghikia A, Podewski E, Libhaber E et al (2013) Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108:366
6. Pearson GD, Veille JC, Rahimtoola S et al (2000) Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of rare diseases (National Institutes of Health) workshop recommendations and review. JAMA 283:1183–1188
7. Witlin AG, Mabie WC, Sibai BM (1997) Peripartum cardiomyopathy: a longitudinal echocardiographic study. Am J Obstet Gynecol 177:1129–1132
8. Forster O, Hilfiker-Kleiner D, Ansari AA et al (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10:861–868
9. Hilfiker-Kleiner D, Kaminski K, Podewski E et al (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589–600
10. Halkein J, Tabruyn SP, Ricke-Hoch M et al (2013) MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123:2143–2154
11. Hilfiker-Kleiner D, Meyer GP, Schieffer E et al (2007) Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50:2354–2355
12. Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:1465–1473
13. Sliwa K, Hilfiker-Kleiner D, Mebazaa A et al (2014) EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail 16:583–591
14. McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
15. Franke J, Zugck C, Wolter JS et al (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 101:1–10
16. Böhm M, Borer J, Ford I et al (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102:11–22
17. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H et al (2013) Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 102:745–753
18. Weil C (1986) The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin 10:25–51
19. Iffy L, Lindenthal J, McArdle JJ, Ganesh V et al (1996) Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. Isr J Med Sci 32:309–312
20. Hopp L, Weisse AB, Iffy L et al (1996) Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol 12:415–418
21. Brenner B (2014) Haemostatic changes in pregnancy. Thromb Res 114:409–414
22. Hilfiker-Kleiner D, Haghikia A, Nonhoff J et al (2015) Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 36:1090–1097
23. Ricke-Hoch M, Bultmann I, Stapel B et al (2014) Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovasc Res 101:587–596